Spanish Research Center Launches Ivermectin Clinical Trial Targeting Mild COVID-19 Patients

Spanish Research Center & Provider Launch Ivermectin Clinical Trial Targeting Mild COVID-19 Patients

Clinical Universidad de Navarra and the Barcelona Institute for Global Health (ISGlobal), a center supported by "la Caixa” Foundation, have launched a clinical trial to investigate the efficacy of ivermectin against COVID-19. The study team will combine ivermectin with Idilfarma to determine whether administration of ivermectin is associated with a shorter clearance time.


Ivermectin was recently evidenced to inhibit the replication of SARS-CoV-2 in vitro at very high doses (Monash University, Australia), but this effect is now being tested in a number of studies from Johns Hopkins University to University of Kentucky in the United States, Tanta University in Egypt, as well as centers in Argentina and Iraq.  

The Study

Titled the SARS-CoV-2 Ivermectin Navarra ISGlobal Trial (SAINT), the Spanish study’s investigators will probe with a randomized trial with 24 participants with mild cases of COVID-19 and no risk factors receiving a single oral dose of ivermectin or placebo less than 48 hours after the onset of the symptoms.

In the study, the newly diagnosed patients don’t require hospitalization, so follow-up is carried out in their homes during their period...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee